Orchid Pharma Ltd GDR (LSE:OCP) - Share price


Stock Report

Orchid Pharma Ltd OCP

Last Price
$-

Day Change
-|-%

As of -
- | USD
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap-
52-Wk Range-
Yield %-
ISINUS68572Y2090
Volume-
P/E-
P/S-
P/CF-

Share Price

Total Returns 04/12/2019

 Chg (%)  
More ...
Orchid Pharma Ltd0.00 
FTSE 100 TR GBP-0.58
 
Financials
201620172018
More ...
Income Statement
Turnover8,734.397,965.046,829.83
Operating Profit255.21-1,093.15-895.05
Net Profit-2,791.13-5,437.76-3,989.63
Reported EPS-6,991.50-12,140.83-8,643.99
Balance Sheet
Current Assets9,727.246,751.256,789.45
Non Current Assets27,860.1625,804.5924,464.25
Total Assets37,587.4032,555.8431,253.69
Current Liabilities12,990.9915,102.1620,125.13
Total Liabilities---
Total Equity-235.55-4,667.48-7,917.60
Cash Flow
Operating Cash Flow2,121.964,061.18162.19
Net Change in Cash-756.25-2,401.90145.15

Company Profile

Orchid Pharma Ltd is involved in the development, manufacturing and marketing of diverse bulk actives, formulations, and nutraceuticals. The company produces various products for cardiovascular, anti-diabetic, neuropsychiatry, and others.

Sector

Drug Manufacturers - Specialty & Generic

Index

Ratios
Comp
More ...
PER (E)0.05
Div Yld (E)0.00
PEG (E)0.00
ROCE-8.75
Op Mrgn-0.13
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Date12/07/1019/07/11
Ex-Div08/07/1015/07/11
Paid05/08/1012/08/11
Amnt0.210.07
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.